LC-MS-MS has become a widely used technique for the fast and sensitive quantitation of small molecules. In this article, this approach has been extended to high-throughput quantitative LC-MS-MS analysis under GLP applications for a drug candidate in development from preclinical animal studies through clinical development.
Bob Wiedemer, Grace Davison Discovery Sciences
Xiaodong Liu and Christopher Pohl, Dionex Corporation
Eric S. Grumbach, Diane M. Diehl and Jeffrey R. Mazzeo, Waters Corporation
Fast, reliable measurements of lipophilicity has a great impact on the compounds' selection process at an early stage of dug discovery. The guest columnit examines HPLC methods for this purpose.
Separation instrument techniques are among the most widely used technologies in the analytical instrumentation market. They span the entire industrial and regional marketplace. The lab separations market includes chromatographic techniques such as analytical and preparative HPLC, GC, IC, TLC, flash, and low pressure LC.
In the mid 1980s the chromatographic application of gases compressed (or liquefied) to supercritical state was tested by research teams from several analytical instrument manufacturers. The recently introduced capillary columns seemed ideal candidates on which to perform such supercritical fluid chromatography (SFC) methods.
A reluctance to make any changes to a validated or compendial method is common, and often well founded.
Excess variability is not acceptable in a pharmaceutical method.
This article gives an overview of the performance of a previously developed system for the ranking of C18 reversed-phase columns applied to different pharmaceutical analyses. The separation of eight different drug substances from their respective impurities was studied. The chromatographic procedure for acetylsalicylic acid, clindamycin hydrochloride, buflomedil hydrochloride, chloramphenicol sodium succinate, phenoxymethylpenicillin and nimesulide was performed according to the corresponding European Pharmacopoeia monograph. The separations of dihydrostreptomycin sulphate and vancomycin were performed according to literature. It was found that that the column ranking system is a helpful tool in the selection of suitable columns in these analyses.
Measurement of chiral purity is a necessary means of quality control for drug substances that exhibit chiral centers. This article describes a simple and practical approach to setting up system suitability and validation for chiral purity assays.
Dissolution testing is a mandatory test for the physical evaluation of solid dosage forms such as capsules, tablets, ointments, and creams. The most basic form of testing measures the rate of dissolution or solubility of a drug tablet. Dissolution testing also can be used in ADME and bioavailability studies, release rates of a drug substance under different conditions, as well as provide information as to the efficacy of in-vivo performance.
September 2006. Top-down and bottom-up are alternative strategies for protein identification and characterization by mass spectrometry. How do they fit into the world of proteomics? What are their implications for separation technology? These questions are addressed in this installment of "Directions in Discovery."
The market for high performance liquid chromatography (HPLC) continues to be one of the most dynamic markets of the analytical instruments industry. A few years ago, the HPLC market began showing signs of maturity with little product innovation and slower growth rates. Although innovations in mass spectrometry (MS) helped to fuel growth, HPLC was an afterthought and considered to be a mere inlet to MS. However, the recent development of fast liquid chromatography (LC) systems is energizing the HPLC market.
The authors work to develop a universal high performance liquid chromatography method that is capable of simultaneously retaining and separating both cations and anions within a single chromatographic analysis for the purpose of quantification in pharmaceutical products.
Implementation of the EU Directive proves to be challenging as regulatory variations among member states continue and questions remain unanswered.
In the clinical trials arena, integrated software solutions help life science companies meet ever more stringent compliance challenges.
Two experts in the GCP field answer common questions about clinical trials and regulatory compliance.
At the same time the pharmaceutical industry faces new and complex issues with the drug development process and clinical trial environment, regulatory policies are increasing and adding to the burden of cost and time to market.
Safety and ethical concerns generate additional reporting and disclosure policies despite efforts to streamline research requirements.
Globally, 2005 sales of pharmaceuticals have been estimated at approximately $550 billion. A significant fraction of this amount was due to the top pharmaceutical companies in the world. The top five companies alone were responsible for total revenues of $168 billion, or 30% of the entire market.
This is the second installment of a two-part series on the practical aspects of configuring and operating a nano liquid chromatography-mass spectrometry (LC-MS) system.
The first of a two-part series addresses HPLC pumps, sample introduction systems, and columns for nanoLC-MS.
